Teva Pharmaceutical Industries Ltd 2021 SR
The report details Teva's 2021 ESG progress, highlighting the issuance of a $5 billion sustainability-linked bond tied to access to medicines and climate targets. The company launched four access to medicines programs and reduced its scope 1 and 2 greenhouse gas emissions by 12.9% compared to 2019. Teva also reported its full scope 3 emissions for the first time and achieved a 1.8% increase in women in executive and senior management positions. Furthermore, the company successfully assessed 100% of its sites handling antimicrobial drug products to minimize discharges.
Company: Teva Pharmaceutical Industries Ltd
Sector: Health Care
Country: Israel
Year: 2021
Type: SR
Pages: 61
Teva Pharmaceutical Industries Ltd
ESG Progress Report
The report details Teva's 2021 ESG progress, highlighting the issuance of a $5 billion sustainability-linked bond tied to access to medicines and climate targets. The company launched four access to medicines programs and reduced its scope 1 and 2 greenhouse gas emissions by 12.9% compared to 2019. Teva also reported its full scope 3 emissions for the first time and achieved a 1.8% increase in women in executive and senior management positions. Furthermore, the company successfully assessed 100% of its sites handling antimicrobial drug products to minimize discharges.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Published
May 1, 2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Renewable Energy
Water Consumption
Total Waste
Women in Management
Employees